Latest News and Press Releases

ZUG, Switzerland, March 06, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company. Attachments ...

ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...

ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Following the Company‘s press release published on March 3, the audited consolidated financial statements for the financial year 2025 and the...

ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...

ZUG, Switzerland, March 04, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment ...

ZUG, Sviss, March 03, 2026 (GLOBE NEWSWIRE) --Árið 2025 náðist mikilvægur árangur, sem gerir Oculis kleift að ná ýmsum klínískum áföngum í rannsóknum á síðari stigum. Þar er fyrst um að ræða...

ZUG, Switzerland, March 03, 2026 (GLOBE NEWSWIRE) --Significant achievements in 2025, enabling multiple near-term clinical milestones across late-stage portfolio, starting with the forthcoming topline...

Significant achievements in 2025, enabling multiple near-term clinical milestones across late-stage portfolio, starting with the forthcoming topline results from DIAMOND Phase 3 trials with OCS-01 eye...

ZUG, Switzerland, Feb. 27, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment ...

ZUG, Switzerland, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares. ...